NASDAQ:AXSM Axsome Therapeutics (AXSM) Stock Price, News & Analysis $168.35 0.00 (0.00%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$168.74 +0.40 (+0.23%) As of 07:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Axsome Therapeutics Stock (NASDAQ:AXSM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Axsome Therapeutics alerts:Sign Up Key Stats Today's Range$166.12▼$170.6450-Day Range$168.35▼$220.8952-Week Range$119.20▼$260.19Volume894,484 shsAverage Volume826,478 shsMarket Capitalization$8.82 billionP/E RatioN/ADividend YieldN/APrice Target$275.74Consensus RatingModerate Buy Company Overview Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. The company uses differentiated product candidates and targeted mechanisms to address conditions with significant unmet medical needs, including depression, sleep disorders, migraine, and other neurological or psychiatric diseases. Axsome’s lead commercial product is Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride), an oral medicine approved in the United States for the treatment of major depressive disorder in adults. The company also commercializes Sunosi (solriamfetol), which is approved to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Axsome acquired the U.S. rights to Sunosi from Jazz Pharmaceuticals in 2022. The company maintains a pipeline of investigational CNS therapies, including candidates being evaluated for disorders such as Alzheimer’s disease agitation, migraine, narcolepsy-related cataplexy, and fibromyalgia. Axsome was founded in 2012 and is headquartered in New York. Its operations and commercial activities are primarily focused on the United States. The company is led by founder and Chief Executive Officer Herriot Tabuteau, M.D.AI Generated. May Contain Errors. Read More Axsome Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreAXSM MarketRank™: Axsome Therapeutics scored higher than 67% of companies evaluated by MarketBeat, and ranked 271st out of 882 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAxsome Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 17 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialAxsome Therapeutics has a consensus price target of $275.74, representing about 63.8% upside from its current price of $168.35.Amount of Analyst CoverageAxsome Therapeutics has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Axsome Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Axsome Therapeutics are expected to grow in the coming year, from ($2.92) to $3.78 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axsome Therapeutics is -44.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axsome Therapeutics is -44.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxsome Therapeutics has a P/B Ratio of 96.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Axsome Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.95% of the float of Axsome Therapeutics has been sold short.Short Interest Ratio / Days to CoverAxsome Therapeutics has a short interest ratio ("days to cover") of 4.36.Change versus previous monthShort interest in Axsome Therapeutics has recently increased by 5.31%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAxsome Therapeutics does not currently pay a dividend.Dividend GrowthAxsome Therapeutics does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment0.13 News SentimentAxsome Therapeutics has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Axsome Therapeutics this week, compared to 8 articles on an average week.Search Interest26 people have searched for AXSM on MarketBeat in the last 30 days. This is an increase of 73% compared to the previous 30 days.MarketBeat Follows9 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Axsome Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,624,805.00 in company stock.Percentage Held by Insiders20.60% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.49% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Axsome Therapeutics' insider trading history. Receive AXSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AXSM Stock News HeadlinesAxsome Therapeutics (AXSM) Gets a Buy from Bank of America SecuritiesOctober 10 at 7:09 PM | theglobeandmail.comAxsome Therapeutics (NASDAQ:AXSM) Stock Price Target Cut by Royal Bank Of CanadaOctober 10 at 2:07 AM | americanbankingnews.comHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fraction of the cost? That's the core advantage options offer traders at every level. The Beginner's Guide to Options breaks down leverage, income strategies, and real trade examples in plain English — including a little-known approach many traders use to reduce costs and improve profit potential. Download your free copy before this offer expires.October 12 at 1:00 AM | Base Camp Trading (Ad)Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?October 7, 2026 | fool.comAxsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2October 7, 2026 | financialpost.comFAxsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2October 7, 2026 | globenewswire.comWhy Baird Sees Growth Potential in Axsome Therapeutics, Inc. (AXSM)October 5, 2026 | finance.yahoo.comFinancial Review: Gyre Therapeutics (NASDAQ:GYRE) and Axsome Therapeutics (NASDAQ:AXSM)October 4, 2026 | americanbankingnews.comSee More Headlines AXSM Stock Analysis - Frequently Asked Questions How have AXSM shares performed this year? Axsome Therapeutics' stock was trading at $182.64 at the beginning of 2026. Since then, AXSM stock has decreased by 7.8% and is now trading at $168.35. How were Axsome Therapeutics' earnings last quarter? Axsome Therapeutics, Inc. (NASDAQ:AXSM) issued its quarterly earnings data on Monday, August, 10th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.89) by $0.10. The company earned $218.38 million during the quarter, compared to analyst estimates of $221.11 million. Axsome Therapeutics had a negative trailing twelve-month return on equity of 265.55% and a negative net margin of 24.68%. Read the conference call transcript. When did Axsome Therapeutics IPO? Axsome Therapeutics (AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager. Who are Axsome Therapeutics' major shareholders? Axsome Therapeutics' top institutional investors include GAMMA Investing LLC and Farther Finance Advisors LLC. Insiders that own company stock include Roger Jeffs, Nick Pizzie, Mark Coleman, Mark E Saad, Mark L Jacobson, Ari Maizel, Herriot Tabuteau and Hunter R Murdock. View institutional ownership trends. How do I buy shares of Axsome Therapeutics? Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Axsome Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Axsome Therapeutics investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Company Calendar Last Earnings8/10/2026Today10/12/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 5 days ago, AXSM's financial health entered the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AXSM CIK1579428 Webaxsome.com Phone(212) 332-3241Fax212-320-0245Employees925Year Founded2012Price Target and Rating Average Price Target for Axsome Therapeutics$275.74 High Price Target$380.00 Low Price Target$205.00 Potential Upside/Downside+63.8%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage21 Analysts Profitability EPS (Trailing Twelve Months)($3.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$183.17 million Net Margins-24.68% Pretax Margin-24.61% Return on Equity-265.55% Return on Assets-28.10% Debt Debt-to-Equity Ratio1.52 Current Ratio1.43 Quick Ratio1.34 Sales & Book Value Annual Sales$776.57 million Price / Sales11.36 Cash FlowN/A Price / Cash FlowN/A Book Value$1.75 per share Price / Book96.20Miscellaneous Outstanding Shares52,381,000Free Float41,591,000Market Cap$8.82 billion OptionableOptionable Beta0.86 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:AXSM) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredUrgent Attention to Executive Order #14363 (Buy This Stock Before Oct. 20thMarc Chaikin, a 60-year Wall Street veteran whose past clients include George Soros and Steve Cohen, built a s...Chaikin Analytics | SponsoredTrump To Relaunch USD?President Trump's summit with Xi Jinping drew headlines for tariffs and trade truces, but the real story may b...Porter & Company | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredUrgent: Invest In ‘Elon’s iPhone’ Before July 22ndEarly Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axsome Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AXSM Stock Alerts